Treatment Trials
Below is a listing of the current treatment clinical trials for cancer offered through the Genesis Regional Cancer Program. Our available trials are listed by site of involvement.
For a complete description of a particular clinical trial, go to the CancerTrials search page. Complete the first four areas on the form: naming the type of cancer; type of trial (treatment); status of trial is "open"; and the protocol number as listed below. Once this information is entered click on the search button at the bottom of the page. You will then get a page listing the trial by title. Click on the title and you will have the entire trial to read and print out as you wish. If you need assistance with this process, contact us.
Breast
NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing 6 Cycles of 5-FU, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC), With or Without Celecoxib, in Patients With Node-Negative Breast Cancer (Temporarily Closed)
NSABP B-37: A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer
NSABP B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women With Stage 0, I or II Breast Cancer
NSABP B-41: Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
NSABP B-42: Clinical Trial to Determine the Efficacy of 5 Years of Letrozole Compared to Placebo in Patients Completing 5 Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenpausal Women With Hormone Receptor Positive Cancer
SWOG S0221: Phase III Trial of Continuous Schedule AC + G vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
SWOG S0226: Phase III Randomized Trial of Anastrozole vs Anastrozole and Fulvestrant as First-Line Therapy for Post Menopausal Women With Metasatic Breast Cancer
SWOG S0622: Phase II Studies of Two Different Schedules of Dasatinib in Bone Metastasis Predominant Metastatic Breast Cancer
CTSU E1105: Randomized Phase III Double-Blind, Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer
CTSU E5103: Double-Blind Phase III Trial of Doxorubicin/Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node (+) and High Risk Lymph Node (-) Breast Cancer
CTSU C40101: Cyclophosphamide and Doxorubicin (CA) (4 vs 6 cycles) vs Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Women with Node Negative Breast Cancer: A 2X2 Factorial Randomized Study
CTSU C40302: Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized Double Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
CTSU C70301: Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer (Companion Study to CTSU 40101)
CTSU NCIC CTG MA.27: A Phase III Randomized Trial of Exemestane vs Anastrozole With or Without Celecoxib in Postmenopausal Women With Receptor-Positive Breast Primary Cancer
CTSU NCIC CTG MA.27B: The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer, MA.27 Companion Study
CTSU NCIC CTG MA.27D: The Association of Breast Density Changes, Plasma Hormone Changes and Breast Cancer Recurrence, MA.27 Companion Study
CTSU IBCSG 24-02: Suppression of Ovarian Function Trial (SOFT)
PACCT-1 (Program for the Assessment of Clinical Cancer Tests): Trial assigning Individualized Options for Treatment
back to top
Carcinoid
SWOG S0518: Phase III Prospective Randomized Comparison of Depot Octreotide + Interferon Alpha vs Depot Octreotide + Bevacizumab in Advanced, Poor Prognosis Carcinoid Patients
back to top
Gastro-Intestinal
CTSU E5202: Randomized Phase III Study Comparing 5-FU, Leucovorin and OXAL vs 5-FU, Leucovorin, OXAL and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
CTSU E5204: Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-FU, and Leucovorin vs Oxaliplatin, 5-FU, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation
CTSU 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With Bevacizumab or Cetuximab or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum
CTSU NCCTG N0147: Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin Plus 5-FU/ Leucovorin With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer
NSABP R-04: Treatment With Two Chemotherapy Drugs Combined With Radiation Therapy for Patients With Rectal Cancer
back to top
Genito-Urinary
CTSU MDA 3410: A Prospective Randomized Phase III Trial Comparing Consolidation Therapy With or Without Strontium-89 (SR 89) Following Induction Chemotherapy in Androgen-Independent Prostate Cancer
CTSU C90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
CTSU E2805: Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients With Resected Renal Cell Cancer
SWOG S0354: Phase II Study of CNTO 328, a Monoclonal Antibody Against IL-6 in Patients With Hormone Refractory Prostate Cancer
SWOG S0421: Phase III Study of Docetaxel and Atrasentan vs Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
back to top
GYN
CTSU GOG-0209: Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF vs Carboplatin/Paclitaxel in Patients With Stage II and IV or Recurrent Endometrial Cancer (Stratum 2, Prior Radiation Therapy--Temporarily Closed)
CTSU GOG-0218: Phase III Trial of Carboplatin and Paclitaxel + Placebo vs Carboplatin and Paclitaxel + Concurrent Bevacizumab Followed by Placebo vs Carboplatin and Paclitaxel + Concurrent and Extended Bevacizumab in Women With Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer
back to top
Head & Neck
CTSU E1302: Phase III Randomized, Placebo-Controlled Trial of Docetaxel vs Docetaxel + ZD1839 (Iressa, getfitinib) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer (Arm C permanently closed)
back to top
Leukemia
SWOG 9007: Cytogenic Studies in Leukemia Patients
SWOG S9910: Leukemia Centralized Reference Lab and Tissue Repositories-Consent to Perform Cellular and Molecular Studies in Leukemia Patients
SWOG S0106: Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy vs Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia
CTSU E2902: Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure
back to top
Lung
SWOG S9925: Lung Cancer Specimen Repository Protocol, Ancillary
SWOG E5597: Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage I Non-Small Cell Lung Cancer
SWOG S0424: Molecular Epidemiology Case-Series of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men (Temporary Closure of female and male smoker strata - 7/15/07)
SWOG S0509: A Phase II Study of Novel Oral Anti-Angiogenic Agent AZD2171 in Malignant Pleural Mesothelioma (Temporary Closure - 2/1/07)
CTSU E1505: Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm)-IIIA Non-Small Cell Lung Cancer
back to top
Lymphoma
SWOG 8819: Central Lymphoma Repository Tissue Procurement Protocol
SWOG 8947: Central Lymphoma Serum Repository Protocol
SWOG 9245: Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease
SWOG S0515: Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab + Bevacizumab for Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
CTSU E4402: Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Low Tumor Burden Patients With Indolent Non-Hodgkin's Lymphoma
back to top
Melanoma
SWOG E1697: Phase III Randomized Study of Four Weeks High Dose IFN-2b in Stage T3-T4 or N1 (microscopic) Melanoma
CTSU E2603: Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 vs Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
back to top
Myeloma
SWOG S0309: Myeloma Specimen Repository Protocol, Ancillary
SWOG S0434: Phase II Trial of BAY 43-9006 (Sorafenib) in Patients With Relapsing or Resistant Multiple Myeloma
back to top